NASDAQ: CBIOCrescent Biopharma Inc Stock
$12.50+0.28 (+2.29%)
Updated Sep 16, 2025
CBIO Price
$12.50
Fair Value Price
N/A
Market Cap
$173.66M
52 Week Low
$10.83
52 Week High
$63.00
P/E
-0.36x
P/B
1.25x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$41.18M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$39M
Beta
1.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CBIO Overview
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CBIO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CBIO
Ranked#366 of 479
Ranked#366 of 479
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.87 | A | |
| $34.98 | A | |
| $7.75 | A |
Be the first to know about important CBIO news, forecast changes, insider trades & much more!
CBIO News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CBIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CBIO is good value based on its book value relative to its share price (1.25x), compared to the US Biotechnology industry average (4.68x)
P/B vs Industry Valuation
CBIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CBIO due diligence checks available for Premium users.
Valuation
CBIO fair value
Fair Value of CBIO stock based on Discounted Cash Flow (DCF)
Price
$12.50
Fair Value
-$0.75
Undervalued by
1,760.56%
CBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.36x
Industry
-95.43x
Market
37.55x
CBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.25x
Industry
4.68x
CBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CBIO's financial health
Profit margin
Revenue
$0.0
Net Income
-$21.8M
Profit Margin
0%
CBIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$157.4M
Liabilities
$18.2M
Debt to equity
0.13
CBIO's short-term assets ($154.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CBIO's short-term assets ($154.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CBIO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.1M
Investing
-$140.0k
Financing
$145.4M
CBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CBIO vs Biotech Stocks
Crescent Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.